STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
· statnews.com · popularity 33/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at statnews.com →
Summary
Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.
Found in: STAT News. Rating basis: single outlet; outlet tier 4; 1 feeds; feed position 4.